• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling.
 
DeviceAeroPace® System
Generic NameTransvenous temporary phrenic nerve stimulator
ApplicantLungpacer Medical USA, Inc.
260 Sierra Drive, Suite 116
Exton, PA 19341
PMA NumberP240012
Date Received04/08/2024
Decision Date12/04/2024
Product Code SDL 
Advisory Committee Anesthesiology
Clinical TrialsNCT03783884
Expedited Review Granted? No
Combination ProductNo
Predetermined Change Control Plan AuthorizedNo
Approval Order Statement  
Approval for AeroPace® System. The AeroPace System is indicated to improve weaning success – increase weaning, reduce ventilator days, and reduce reintubation - in patients ages 18 years or older on mechanical ventilation >= 96 hours and who have not weaned.
Approval OrderApproval Order
SummarySummary of Safety and Effectiveness
LabelingLabeling
Labeling Part 2
Post-Approval StudyShow Report Schedule and Study Progress
Supplements:  S001 S002 S003 
-
-